News Sort by Year All Years 2024 (12) 2023 (28) 2022 (31) 2021 (33) 2020 (37) 2019 (7) 2018 (4) Search September 26, 2024 TFF Pharmaceuticals’ Technology Generates Superior Inhalational Dry Powder Formulations for Pulmonary Drug Delivery September 11, 2024 TFF Pharmaceuticals Partners with Emory University and BARDA to Develop a Dry Powder Inhaled mRNA-based Treatment for Influenza and COVID September 10, 2024 TFF Pharmaceuticals Announces Positive Preclinical Data from Bivalent Universal Influenza Vaccine Candidates Manufactured by TFF Following Intranasal Immunization September 3, 2024 TFF Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference August 14, 2024 TFF Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update August 6, 2024 TFF Pharmaceuticals Provides Continued Positive Outcomes from Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant Rejection June 26, 2024 TFF Pharmaceuticals Engages Outcome Capital As a Strategic Advisor for Evaluating Partnership and Licensing Opportunities June 24, 2024 TFF Pharmaceuticals Provides Regulatory Update on Tacrolimus Inhalation Powder (TFF TAC) Clinical Program for the Prevention of Lung Transplant Rejection May 23, 2024 TFF Pharmaceuticals and Leidos to Advance Next-Generation Biodefense Countermeasures Under the DARPA PPB Program into Preclinical Testing May 20, 2024 TFF Pharmaceuticals and Cleveland Clinic to Advance Multivalent Universal Influenza Vaccine Candidates into Preclinical Testing
